Mesenchymal stem cell overexpressing IL-1Ra and application thereof

By overexpressing IL-1Ra in MSCs, it promotes its migration, and solves the problem of insufficient migration function of MSCs, significantly improves anti-inflammatory and repair capabilities, and significantly improves the effect of treating inflammatory diseases.

CN119082044AActive Publication Date: 2024-12-06THE SECOND HOSPITAL OF SHANDONG UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411579013.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-07
Publication Date
2024-12-06
Estimated Expiration
2044-11-07

AI Technical Summary

Technical Problem

In the prior art, mesenchymal stem cells (MSCs) have limited migration functions in the treatment of inflammatory diseases and tissue damage repair, affecting their anti-inflammatory and repair capabilities.

Method used

By overexpressing interleukin-1 receptor antagonist (IL-1Ra) in MSCs, the migration of MSCs to tissue injury sites is promoted, and their anti-inflammatory ability and tissue injury repair ability are improved.

Benefits of technology

It significantly increased the number and anti-inflammatory ability of MSCs in tissue damage sites and improved the efficacy of treating inflammatory diseases such as hemorrhagic cystitis and acute pneumonia lesions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082044A_ABST
    Figure CN119082044A_ABST
Patent Text Reader

Abstract

The invention provides an IL-1Ra overexpression mesenchymal stem cell and application thereof, and belongs to the technical field of biological medicine. By overexpressing IL-1Ra in the MSCs, the migration function of the MSCs is remarkably improved, and the number of the MSCs homing to a tissue injury part is remarkably increased; in addition, the MSCs overexpressing the IL-1Ra can also secrete the IL-1Ra to achieve the synergistic anti-inflammatory effect with the MSCs, so that the anti-inflammatory capacity and tissue damage repair capacity of the MSCs are remarkably improved, and the treatment effect of the MSCs is improved. The MSCs with overexpressed IL-1Ra can be used for treating various local or systemic inflammatory diseases, and has a good curative effect in treatment of hemorrhagic cystitis and acute pneumonia diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to mesenchymal stem cells overexpressing IL-1Ra and applications thereof. Background Art

[0002] Mesenchymal stem cells (MSCs) are a type of adult stem cell that has the ability to self-renew and differentiate into a variety of cells, such as fat cells, chondrocytes, bone cells, muscle cells, and nerve cells. MSCs are mainly distributed in the interstitium of tissues and organs such as bone marrow, fat, and umbilical cord. Under physiological conditions, the main function of MSCs is to maintain the self-stability (homeostasis) of tissues and organs. MSCs have paracrine functions and can regulate the immune system by secreting a variety of cytokines, promote angiogenesis, and promote the regeneration and repair of cells, tissues, and organs; in addition, MSCs can also directly interact with immune cells (such as T lymphocytes, macrophages, dendritic cells, etc.) to regulate immune cell functions, thereby inhibiting immune responses and reducing tissue and organ damage caused by excessive immune responses. In recent years, studies have found that exosomes derived from MSCs have the function of promoting the regeneration and repair of various tissues such as nerves and blood vessels. Given the powerful biological functions of MSCs in inhibiting inflammation and promoting tissue damage repair, MSCs are widely used in clinical research or clinical trials for the treatment of inflammatory diseases such as graft-versus-host disease (GVHD), systemic lupus erythematosus, inflammatory bowel disease, pneumonia, and arthritis.

[0003] Currently, MSCs have limited ability to treat inflammatory diseases or promote tissue damage and repair. Many studies have shown that the number of MSCs in the tissue damage site is one of the key factors that determine its therapeutic effect, and factors such as pathological state and immune environment affect the migration or homing function of MSCs. Therefore, finding technologies or methods that can improve the migration function of MSCs to improve the anti-inflammatory ability and tissue damage repair ability of MSCs is a hot topic in current research.

[0004] Interleukin-1α (IL-1α) and interleukin-1β (IL-1β) are important pro-inflammatory factors. IL-1α and IL-1β first bind to the receptor IL-1R1 on their target cells, and then interact with auxiliary receptors to form a ternary complex, activating the signaling pathway in the target cells, thereby inducing the expression of a series of inflammation-related molecules, leading to the occurrence of inflammation. Interleukin-1 receptor antagonist (IL-1Ra) can bind to IL-1R1, thereby blocking the inflammatory response induced by IL-1α and IL-1β. Anakinra is a recombinant human IL-1Ra drug that has been used in the treatment of rheumatic diseases such as rheumatoid arthritis and some non-rheumatic inflammatory diseases.

[0005] MSCs have the characteristics of high proliferation, easy isolation, culture and expansion, easy transfection and expression of exogenous genes, and low immunogenicity. They have important clinical application value in cell therapy and gene therapy and are considered to be ideal target cells for tissue engineering, cell therapy and gene therapy. The patent application with publication number "CN116103243A" (application number 202310051400.4) provides an application of mesenchymal stem cells overexpressing IL-1Ra in the prevention and treatment of GVHD. The lentivirus is prepared by packaging the plasmid overexpressing IL-1Ra, and then infecting MSCs. After resistance screening, a stable cell line is obtained. The cell line can be used for the prevention of aGVHD (acute graft-versus-host disease) with good preventive effect. The patent application with publication number "CN117467666A" (application number 202311212422.0) provides a mesenchymal stem cell overexpressing IL-1Ra and its application. During hematopoietic stem cell transplantation, MSCs overexpressing IL-1Ra are infused simultaneously with hematopoietic stem cells, or infused successively, which can prevent GVHD, promote hematopoietic stem cell engraftment, support hematopoietic stem cell proliferation, and improve the success rate of hematopoietic stem cell transplantation; in the mouse ARDS (acute respiratory distress syndrome) model, MSCs exosomes overexpressing IL-1Ra showed good therapeutic effects. However, none of the above patents reveal the effect of IL-1Ra overexpression on MSCs migration.

[0006] At present, exploring a technology or method that can enhance the chemotactic function of MSCs to enhance the anti-inflammatory ability and tissue damage repair ability of MSCs is of great significance to my country's medical field. Summary of the invention

[0007] In view of the deficiencies of the prior art, the present invention provides a mesenchymal stem cell overexpressing IL-1Ra and its application. By overexpressing IL-1Ra in MSCs, the migration of MSCs to the tissue damage site can be promoted, thereby improving the anti-inflammatory ability and tissue damage repair ability of MSCs.

[0008] The technical solution of the present invention is as follows: A mesenchymal stem cell overexpressing IL-1Ra overexpresses IL-1Ra in the mesenchymal stem cell.

[0009] The accession number of the IL-1Ra mRNA sequence in GenBank is NM_000577.5.

[0010] The accession number of the amino acid sequence of IL-1Ra in GenBank is NP_776214.1, NP_776213.1, NP_000568.1, NP_776215.1, NP_001305843.1 or NP_001366289.1.

[0011] Preferably, the method for overexpressing IL-1Ra in mesenchymal stem cells is to prepare a lentivirus by packaging a plasmid containing IL-1Ra, then infect mesenchymal stem cells with the lentivirus, and obtain mesenchymal stem cells overexpressing IL-1Ra after screening.

[0012] Preferably, the source of the mesenchymal stem cells is umbilical cord, bone marrow, fat or dental pulp.

[0013] Preferably, the source of the mesenchymal stem cells is umbilical cord.

[0014] The use of the mesenchymal stem cells overexpressing IL-1Ra in the preparation of drugs for treating inflammatory diseases.

[0015] Preferably, the inflammatory disease is hemorrhagic cystitis or acute pulmonary lesions.

[0016] Further preferably, the mesenchymal stem cells overexpressing IL-1Ra treat inflammatory diseases by promoting the migration of mesenchymal stem cells.

[0017] The use of the mesenchymal stem cells overexpressing IL-1Ra in the preparation of tissue damage repair drugs.

[0018] The use of the mesenchymal stem cells overexpressing IL-1Ra in promoting the migration of mesenchymal stem cells.

[0019] Preferably, the mesenchymal stem cells overexpressing IL-1Ra are used to promote the migration of mesenchymal stem cells to a site of tissue damage.

[0020] Beneficial effects: The present invention found that by overexpressing IL-1Ra in MSCs, the migration of MSCs to the site of tissue damage can be promoted, so that the number of MSCs in the site of tissue damage is significantly increased; in addition, MSCs overexpressing IL-1Ra can also secrete IL-1Ra to achieve a synergistic anti-inflammatory effect, thereby significantly improving the anti-inflammatory ability and tissue damage repair ability of MSCs. Compared with normal MSCs, MSCs overexpressing IL-1Ra have significant therapeutic effects in the treatment of hemorrhagic cystitis and acute pulmonary inflammatory diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1. Construction and identification of MSCs overexpressing IL-1Ra. Figure A is a map of the recombinant expression vector overexpressing IL-1Ra; Figure B is the expression of IL-1Ra at the mRNA level; Figure C is the expression of IL-1Ra at the protein level; Figure D is the concentration of IL-1Ra secreted in the cell culture supernatant.

[0022] Figure 2 . Expression of CXCR5 at the mRNA level in MSCs overexpressing IL-1Ra.

[0023] Figure 3 . Transwell chamber was used to detect the migration ability of MSCs overexpressing IL-1Ra. Figure A is a crystal violet staining photo of Mock-MSCs passing through the Transwell chamber; Figure B is a crystal violet staining photo of oeIL-1Ra-MSCs passing through the Transwell chamber; Figure C is the statistical analysis result of the number of migrated cells.

[0024] Figure 4 . The therapeutic effect of MSCs overexpressing IL-1Ra on hemorrhagic cystitis. Figure A shows the hematuria of rats in each group detected by hematuria test strips; Figure B shows the statistical analysis results of hematuria scores; Figure C shows the gross appearance of the bladder of rats in each group; Figure D shows the statistical analysis results of the ratio of bladder wet weight to body weight of rats in each group.

[0025] Figure 5 . The chemotaxis and homing ability of MSCs overexpressing IL-1Ra to the bladder tissue of rats with hemorrhagic cystitis. Figure A shows the results of human CD105 immunohistochemical staining of bladder tissue of rats in each group; Figure B shows the statistical analysis results of the number of CD105 positive cells in the Mock-MSCs treatment group and the oeIL-1Ra-MSCs treatment group.

[0026] Figure 6 . The therapeutic effect of MSCs overexpressing IL-1Ra on acute pulmonary inflammatory lesions. Figure A shows the chest imaging examination results of mice in each group; Figure B shows the hematoxylin and eosin staining results of lung pathological sections of mice in each group. DETAILED DESCRIPTION

[0027] The following is explained in conjunction with specific embodiments: Source of experimental materials: psPAX2: purchased from Shanghai Genetech Technology Co., Ltd.; pMD2.G: purchased from Shanghai Genetech Technology Co., Ltd.; Lipofectamine 3000 transfection reagent: purchased from Thermo Fisher Scientific; Opti-MEM medium: purchased from Thermo Fisher Scientific; DMEM / F12 complete medium: 10% (10 mL / 100 mL) FBS, 0.272 g / L L-glutamine, 10 ng / mL bFGF (fibroblast growth factor), 100 U / mL penicillin, and 0.1 mg / mL streptomycin.

[0028] Example 1: Construction and identification of MSCs overexpressing IL-1Ra 1. Construction of MSCs overexpressing IL-1Ra (oeIL-1Ra-MSCs) (1) Isolation, culture and expansion of MSCs Umbilical cord tissue of newborns (the mother has signed an informed consent form), added an appropriate amount of DMEM / F12 complete medium, cut the umbilical cord tissue into pieces as much as possible with sterile scissors in a sterile operating table, and then digested it with 1% collagenase II solution and 0.125% trypsin solution for 30 minutes respectively to obtain digestion solution; the digestion solution was collected into a centrifuge tube, centrifuged at 1500 rpm for 10 minutes, the supernatant was discarded, and an appropriate amount of DMEM / F12 complete medium was added to the cell pellet to resuspend it to obtain a resuspension; the resuspension was transferred to a cell culture bottle and placed in an incubator with saturated humidity, 37°C, and 5% CO2 for incubation. On the third day, the supernatant was aspirated to remove non-adherent cells and tissue fragments, and fresh DMEM / F12 complete medium was added to continue culturing, and fresh medium was replaced every other day thereafter.

[0029] When the cell confluence reached 80%, the supernatant was aspirated, the cells were washed once with PBS buffer, and 0.25% trypsin solution was added for digestion. After the cells became round and floated, DMEM / F12 complete medium was added to terminate the reaction to obtain the digestion solution; the digestion solution was collected into a centrifuge tube, centrifuged at 1200 rpm for 5 minutes, the supernatant was discarded, an appropriate amount of DMEM / F12 complete medium was added to the cell pellet to resuspend it, the cell suspension was transferred to a cell culture flask, and cultured according to the above incubation conditions; the cultured fourth-generation cells were used for subsequent experiments.

[0030] (2) Construction of oeIL-1Ra-MSCs The sequence with accession number NM_000577.5 in GenBank was used as the target gene, and the target gene was connected to the GV367 vector (Ubi-MCS-SV40-EGFP-IRES-puromycin) to construct the recombinant expression vector oeIL-1Ra-GV367. The above work was entrusted to Shanghai Jikai Gene Technology Co., Ltd. The map of the recombinant expression vector is shown in Figure 1 As shown in Figure A.

[0031] 293T cells (ATCC CRL-3216) were used as tool cells and mixed in a mass ratio of oeIL-1Ra-GV367:psPAX2:pMD2.G=4:3:1. Lipofectamine 3000 transfection reagent was used to assist in transfection of 293T cells to package lentivirus. The cells were incubated in an incubator for 48 hours, and the cell supernatant was collected and centrifuged at 100,000 rpm for 2 hours in an ultracentrifuge. The supernatant was removed and the precipitate was resuspended with PBS buffer to obtain oeIL-1Ra lentivirus.

[0032] The virus titer was determined by infecting 293T cells with lentivirus at 3×10 8 It can be used if the concentration is above TU / mL.

[0033] Resuspend the MSCs obtained in step (1) in Opti-MEM medium and plate them at a concentration of 2 × 10 5 The cells were inoculated into 6-well plates at a density of 10 cells / well, and oeIL-1Ra lentivirus was added at an MOI of 40 (multiplicity of infection, the ratio of virus amount to cell number). After incubation in the incubator for 12 hours, the culture medium was replaced with DMEM / F12 complete medium and continued to be cultured. After 3 days, the cells were digested according to the method described in step (1). 1×10 5 The percentage of GFP positive cells was detected by flow cytometry, which was the virus infection positive rate. Puromycin with a final concentration of 2 μg / mL was added to the cells. After 2 days, the uninfected cells died and floated. The surviving cells were positive cells. The positive cells were cultured and amplified to obtain the MSCs stably transfected cell line oeIL-1Ra-MSCs that overexpressed IL-1Ra.

[0034] The irrelevant sequence (5'-TTCTCCGAACGTGTCACGT-3') was connected to the GV367 vector to construct the recombinant expression vector Mock-GV367. Then, the Mock lentivirus was prepared and infected with MSCs according to the same method as above to obtain Mock-MSCs as a blank control group for subsequent experiments.

[0035] 2. Identification of oeIL-1Ra-MSCs (1) RT-PCR identification oeIL-1Ra-MSCs were digested with 0.25% trypsin solution, counted, and 1×10 6 cells, extracted cell mRNA, and reverse transcribed it into cDNA; using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal reference gene, the relative expression of IL-1Ra at the mRNA level was detected by real-time fluorescence quantitative PCR (RT-PCR).

[0036] Among them, the RT-PCR primers used for detecting IL-1Ra are IL-1Ra-F and IL-1Ra-R, the primer sequences are shown in SEQ ID NOs.1~2, respectively, and the product size is 167bp; the RT-PCR primers used for detecting GAPDH are GAPDH-F and GAPDH-R, the primer sequences are shown in SEQ ID NOs.3~4, respectively, and the product size is 211bp.

[0037] The results are as follows Figure 1 As shown in Figure B; it can be seen from Figure B that compared with the blank control group, the relative expression level of IL-1Ra at the mRNA level in the stably transfected cell line oeIL-1Ra-MSCs was significantly increased.

[0038] (2) Western blot identification Take 1×10 6 oeIL-1Ra-MSCs were lysed with RIPA lysis buffer to prepare protein samples; GAPDH was used as the internal reference protein, and the expression of IL-1Ra at the protein level was detected by Western blot. The concentration of protein samples was determined by BCA method, and the same amount of protein samples were separated by SDS-PAGE gel electrophoresis and transferred to PVDF membrane by membrane transfer instrument. The PVDF membrane was blocked with 5% BSA at room temperature for 1 hour, and anti-human IL-1Ra antibody was added at 4℃ overnight; the membrane was washed with TBST, and the secondary antibody labeled with horseradish peroxidase was added and incubated at room temperature for 1 hour; the membrane was washed with TBST and developed by chemiluminescent substrate.

[0039] The results are as follows Figure 1 As shown in Figure C; it can be seen from Figure C that compared with the blank control group, the relative expression level of IL-1Ra at the protein level in the stably transfected cell line oeIL-1Ra-MSCs was significantly increased.

[0040] (3) ELISA identification oeIL-1Ra-MSCs were cultured in DMEM / F12 complete medium at 37°C and 5% CO2 for 72 hours, and the cell culture supernatant was collected. The OD value of the supernatant was measured by microplate reader according to the instructions of the ELISA kit. 450 OD 630 ; Draw a standard curve, and then calculate the concentration of IL-1Ra in the supernatant based on the standard curve.

[0041] The results are as follows Figure 1 As shown in Figure D; it can be seen from Figure D that compared with the blank control group, the concentration of IL-1Ra in the cell culture supernatant of the stably transfected cell line oeIL-1Ra-MSCs was significantly increased, which indicates that MSCs overexpressing IL-1Ra can secrete IL-1Ra outside the cells.

[0042] (4) Expression of chemokine CXCR5 The relative expression of chemokine CXCR5 in oeIL-1Ra-MSCs was detected by RT-PCR, wherein the RT-PCR primers used were CXCR5-F and CXCR5-R, the primer sequences were shown in SEQ ID NOs.5~6, respectively, and the product size was 233bp.

[0043] The results are as follows Figure 2 As shown. Figure 2 It can be seen that the relative expression of CXCR5 at the mRNA level in oeIL-1Ra-MSCs was significantly increased compared with the blank control group, which suggests that overexpression of IL-1Ra may improve the chemotactic ability of MSCs by upregulating the expression of CXCR5.

[0044] In summary, compared with the blank control group, the expression levels of IL-1Ra at both mRNA and protein levels in the stably transfected cell line oeIL-1Ra-MSCs were significantly increased, and the concentration of IL-1Ra in the cell culture supernatant was significantly increased, indicating that MSCs overexpressing IL-1Ra were successfully constructed.

[0045] Example 2: Migration ability test of MSCs overexpressing IL-1Ra Resuspend oeIL-1Ra-MSCs in DMEM / F12 complete medium without FBS to make the cell concentration of the cell resuspension solution 1×10 5 / mL; meanwhile, Mock-MSCs were used as blank control group.

[0046] The chemotaxis test was performed using a 24-well chemotaxis chamber with a pore size of 8 μm. 100 μL of the above cell resuspension was added to the upper chamber (chamber), and 600 μL of DMEM / F12 complete medium was added to the lower chamber; after 24 hours, the excess liquid in the upper chamber was shaken off, and the non-migrated cells on the inner side of the upper chamber membrane were wiped off with a cotton swab, and the upper chamber was fixed with 4% paraformaldehyde solution for 20 minutes, and then the outer side of the upper chamber membrane was stained with 0.5% crystal violet staining solution for 10 minutes. Five fields of view were randomly selected under a microscope to observe the cell migration, and the number of migrated cells was counted.

[0047] The results are as follows Figure 3 As shown, Figures A to B show the cell migration outside the upper chamber membrane, and Figure C shows the statistical results of the number of migrated cells in each group. Figure 3 It can be seen that compared with the blank control group, the number of oeIL-1Ra-MSCs migration increased significantly (**** p <0.0001), which indicates that the chemotactic ability of MSCs overexpressing IL-1Ra is significantly improved.

[0048] Application Example 1: Treatment of hemorrhagic cystitis with MSCs overexpressing IL-1Ra 1. Construction of the rat model of hemorrhagic cystitis Twenty-four male Wistar rats (250-280 g, 6 weeks old) were selected, of which 6 rats were used as the normal control group (control, con), and the normal control group did not receive any treatment; the remaining 18 rats were intraperitoneally injected with 40 mg / mL cyclophosphamide solution on day 0, with an injection dose of 150 mg / kg to establish a rat model of hemorrhagic cystitis.

[0049] Eighteen rats with hemorrhagic cystitis were randomly divided into three groups, with six rats in each group, namely, the disease model group (hemorrhagic cystitis), the Mock-MSCs treatment group, and the oeIL-1Ra-MSCs treatment group. The disease model group did not receive any intervention. The Mock-MSCs treatment group was infused with Mock-MSCs through the tail vein on the first and third days, respectively, and the oeIL-1Ra-MSCs treatment group was infused with oeIL-1Ra-MSCs through the tail vein on the first and third days, respectively. The infusion dose was 1×10 6 Piece / piece.

[0050] 2. Observation of treatment effect (1) Blood and urine test strip evaluation On the 7th day, urine of each rat was collected using blood and urine test strips, and the comparison and scoring were performed according to the standard colorimetric chart of the blood and urine test strips, and statistical analysis was performed.

[0051] The hematuria of rats shown by the hematuria test paper is as follows Figure 4 As shown in Figure A, the hematuria score results are as follows Figure 4 As shown in Figure B (** p <0.01, *** p <0.001, **** p <0.0001). As shown in Figures A and B, compared with the Mock-MSCs treatment group, the hematuria of rats in the oeIL-1Ra-MSCs treatment group was significantly alleviated.

[0052] (2) Observation and weighing of rat bladder tissue The rats were euthanized, and the bladder tissues were collected for photographing and weighing (wet weight) to observe the changes in the bladder tissues of the rats.

[0053] Photographic images of bladder tissue Figure 4 As shown in Figure C, the statistical analysis results of the ratio of bladder tissue wet weight to body weight are as follows Figure 4 As shown in Figure D (** p <0.01, **** p<0.0001). As shown in Figures C-D, compared with the Mock-MSCs treatment group, the bladder tissue of the rats in the oeIL-1Ra-MSCs treatment group had less bleeding, smaller volume, and significantly lower wet weight.

[0054] (3) Chemotaxis and homing ability of oeIL-1Ra-MSCs to rat bladder tissue The bladder tissue was fixed with 4% paraformaldehyde solution and embedded in paraffin to prepare 8 mm bladder tissue sections. The bladder tissue sections were stained with hematoxylin and eosin according to conventional methods, and the human CD105 cells (a marker molecule for mesenchymal stem cells) were marked by immunohistochemistry to observe the chemotaxis and homing ability of oeIL-1Ra-MSCs to rat bladder tissue.

[0055] The results are as follows Figure 5 As shown, Figure A shows the results of human CD105 immunohistochemical staining of rat bladder tissues in each group, and Figure B shows the statistical analysis results of the number of CD105 positive cells (light brown and larger cells) in each group (* p <0.05). Figure 5 It was found that the localization of oeIL-1Ra-MSCs in the bladder tissue of the rat model of hemorrhagic cystitis was significantly increased.

[0056] In summary, the therapeutic effect of MSCs overexpressing IL-1Ra in the treatment of hemorrhagic cystitis was better than that of the blank control group (Mock-MSCs treatment group), and the chemotaxis of MSCs overexpressing IL-1Ra to the site of inflammatory tissue damage in the bladder was significantly increased.

[0057] Application Example 2: Treatment of Acute Pneumonic Lesions with MSCs Overexpressing IL-1Ra 1. Construction of mouse model of acute pneumonia Dissolve lipopolysaccharide (LPS) in PBS buffer to prepare an LPS solution with a concentration of 2 mg / mL.

[0058] Twenty-four male Balb / c mice (20-22g, 6-8 weeks old) were selected and adaptively raised for 1 week. Six mice were used as the normal control group (control), and the remaining 18 mice were instilled with LPS solution in the trachea at a dose of 5 mg / kg to establish an acute pneumonia mouse model; the normal control group was instilled with an equal amount of PBS buffer.

[0059] Eighteen ALI mice were randomly divided into three groups, each with six mice, namely, LPS model group, Mock-MSCs treatment group and oeIL-1Ra-MSCs treatment group. Mock-MSCs were instilled into the trachea of ​​mice in the Mock-MSCs treatment group 4 hours after LPS instillation, and oeIL-1Ra-MSCs were instilled into the trachea of ​​mice in the oeIL-1Ra-MSCs treatment group 4 hours after LPS instillation. The instillation dose was 5×10 5 The LPS model group was instilled with an equal amount of PBS buffer.

[0060] 2. Observation of treatment effect (1) Chest imaging examination The chest imaging of mice in each group was performed using small animal micro-CT technology to evaluate the extent of lung lesions in mice. The results are as follows: Figure 6 As shown in Figure A.

[0061] Depend on Figure 6 As shown in Figure A, the brightness of the lungs of mice in the normal control group was normal, with no obvious abnormalities; patchy exudative shadows were visible in the lungs of mice in the LPS model group, and some had actual lesions; the inflammatory lesions in the lungs of mice in the Mock-MSCs treatment group were alleviated compared with those in the LPS model group; compared with the Mock-MSCs treatment group, the inflammatory lesions in the lungs of mice in the oeIL-1Ra-MSCs treatment group were more significantly alleviated, with no obvious exudative shadows.

[0062] (2) Pathological section observation The lungs of mice in each group were pathologically sectioned and stained with hematoxylin and eosin, and then the extent of lung lesions in mice was observed under a microscope. Figure 6 As shown in Figure B.

[0063] Depend on Figure 6 As shown in Figure B, a small number of inflammatory cells were observed in the lungs of mice in the normal control group, the alveoli were full, the alveolar walls were thin and intact, and there was no exudation in the alveolar cavity; inflammatory cells were observed in the lungs of mice in the LPS model group, the pulmonary interstitium was widened, the alveoli collapsed, the alveolar cavity exudated, and the pulmonary capillaries were congested and hemorrhaged; the edema, hemorrhage, and congestion in the lungs of mice in the Mock-MSCs treatment group were reduced compared with those in the LPS model group; compared with the Mock-MSCs treatment group, the edema, hemorrhage, and congestion in the lungs of mice in the oeIL-1Ra-MSCs treatment group were more significantly reduced.

[0064] In conclusion, MSCs overexpressing IL-1Ra can effectively treat acute pulmonary lesions.

Claims

1. A mesenchymal stem cell overexpressing IL-1Ra, which overexpresses IL-1Ra in the mesenchymal stem cell.

2. The mesenchymal stem cell according to claim 1, wherein The method for overexpressing IL-1Ra in mesenchymal stem cells comprises packaging a plasmid containing IL-1Ra to prepare a lentivirus, then infecting the mesenchymal stem cells with the lentivirus, and obtaining the mesenchymal stem cells overexpressing IL-1Ra after screening.

3. The mesenchymal stem cell according to claim 1, characterized in that The mesenchymal stem cells are derived from umbilical cord, bone marrow, fat or dental pulp.

4. The mesenchymal stem cell according to claim 1, characterized in that The source of the mesenchymal stem cells is umbilical cord.

5. The use of mesenchymal stem cells overexpressing IL-1Ra according to claim 1, characterized in that: Used in preparing drugs for treating inflammatory diseases.

6. The use according to claim 5, characterized in that The inflammatory disease is hemorrhagic cystitis or acute pneumonia.

7. The use according to claim 5, characterized in that The mesenchymal stem cells overexpressing IL-1Ra treat inflammatory diseases by promoting the migration of mesenchymal stem cells.

8. The use of mesenchymal stem cells overexpressing IL-1Ra according to claim 1, characterized in that: Used in the preparation of tissue damage repair drugs.

9. The use of mesenchymal stem cells overexpressing IL-1Ra according to claim 1, characterized in that: Used to promote the migration of mesenchymal stem cells.

10. The use according to claim 9, characterized in that Used to promote the migration of mesenchymal stem cells to sites of tissue damage.

Citation Information

Patent Citations

  • Medicine for resisting cytokine storm caused by SARS-CoV2 virus infection

    CN114404572A

  • Mesenchymal stem cell overexpressing human IL-1Ra and application thereof

    CN116103243A

  • Mesenchymal stem cell overexpressing IL-1Ra and application thereof

    CN117467666A

  • Pharmaceutical composition for treatment or prevention of Ketamine-induced cystitis comprising of mesenchymal stem cells

    KR1020180003325A